Therefore, we need more studies to clarify the roles and mechanisms of genes such as CCDC102A, RD3L, and SLC29A2 in AML, which can provide a more reliable theoretical basis for prognostic assessment as screening new therapeutic targets for AML treatment. This evidence concerns the gene RD3L and acute myeloid leukemia.